Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata affects women and young adults most, with low SDI regions seeing the highest increase, and new treatments like JAK inhibitors are being explored.

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

Nyctanthes arbor-tristis has potential health benefits and needs more research for safe medicinal use.

The supplement improved hair growth and quality in men with thinning hair and was safe to use.

Dutasteride and finasteride do not increase mood disorder risk in men with hair loss.

Topical finasteride is well-tolerated and satisfies most users with minimal side effects.

Dutasteride is safe and effective for treating hair loss, but may decrease libido.

Janus kinase inhibitors help hair regrowth in kids with alopecia areata but need more safety research.

Janus kinase inhibitors can help children with alopecia areata regrow hair but may have some risks.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Compound glycyrrhizin combined with conventional treatments effectively and safely promotes hair regrowth in alopecia areata patients.

Compound glycyrrhizin with conventional treatments is effective and safe for promoting hair regrowth in alopecia areata.

Baricitinib is effective and safe for treating alopecia areata in Korea.

Dutasteride is more effective than finasteride for long-term hair growth in men with androgenic alopecia.

17α-Estradiol solution safely improves hair density and thickness in female pattern hair loss.

Low-dose dutasteride effectively and safely promotes hair growth in men.

Taking spironolactone doesn't increase the chance of breast cancer coming back.

PRP therapy can help regrow hair and improve hair thickness.

Bhrungaraj (Eclipta alba) shows potential for drug development based on its traditional uses and pharmacological evidence.

A standard protocol for alopecia areata clinical trials was created to improve consistency and encourage more research.

The new FDA labeling rules provide more detailed drug safety information for pregnant and breastfeeding women, but more data is needed on the risks of many dermatologic drugs.

Lurasidone is effective for bipolar depression and schizophrenia, but more safety data is needed.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

More education and access to professional scalp micropigmentation services are needed for safety.

Methotrexate's effectiveness for maintaining hair regrowth in alopecia totalis is unclear due to limited and biased data.

Topical minoxidil effectively and safely treats female pattern hair loss, but other treatments need more research.